IPI takes the lead in a New Era in Iraqi Pharmaceuticals
For the very first time in Iraq, we are thrilled to be making history by authorizing PHARMACARE, a European company, to produce Palbociclib IPI, a vital medication for breast cancer patients. This achievement has captured the attention of Arabic and European media outlets.
Wael Louay Mirza, our COO, highlighted the drug’s effectiveness and emphasized the significance of this step for the Iraqi pharmaceutical industry during the press conference in Dubai. This initiative aligns with the government's program to localize pharmaceutical production, including the drug Palbociclib IPI, under the Ministry of Health's regulations.
Since 2022, we have been producing cancer treatment drugs according to international standards and are set to introduce thirty-two new pharmaceutical substances for cancer patients.
Read the full articles through the links below:
Al Wahda
Arqam
Ajman
Shourouk News
Nabd
Al Jarida
Masr Times
Al Tabib
Arab 24
Akhbar Al Khaleej
Arab News
https://alwahdanews.ae/300262/
